CHARLES MORALES: Open Payments
NPI 1073519161 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,287 in 62 payments from 14 companies in 2025. Trend: 2023 $1,036 · 2024 $1,422 · 2025 $1,287
Food & beverage: $1,191Education: $97
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 18 | $348 |
| ABBVIE INC. | 12 | $195 |
| Lilly USA, LLC | 9 | $187 |
| Amgen Inc. | 7 | $163 |
| Insulet Corporation | 1 | $86 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Dexcom, Inc. | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $31 |
| GlaxoSmithKline, LLC. | 1 | $30 |
Products named: SYNTHROID, JARDIANCE, Ozempic, MOUNJARO, OMNIPOD, EVENITY, Repatha, Rybelsus.
Industry payments across CA — which companies pay providers there.
